BioCentury
ARTICLE | Clinical News

Legend reports 15 months PFS for anti-BCMA CAR; questions over trial sites linger

December 7, 2018 5:55 PM UTC

Data presented on the most advanced Chinese CAR product at the American Society of Hematology (ASH) meeting don't shed much light on outstanding questions related to the company's data reports from the trial, but do help benchmark the efficacy to expect from the first CAR T cell therapies against BCMA (tumor necrosis factor receptor superfamily member 17; TNFRSF17; CD269) when viewed alongside bb2121 from bluebird bio inc. (NASDAQ:BLUE) and Celgene Corp. (NASDAQ:CELG).

The Nanjing Legend Biotech Co. Ltd. unit of GenScript Biotech Corp. (HKSE:1548) reported progression-free survival (PFS) data and overall survival (OS) data for anti-BCMA CAR T therapy LCAR-B38M that are not yet mature, but if they continue their current trend could offer a favorable risk-benefit profile, according to one doctor's opinion...